X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (33) 33
female (31) 31
index medicus (31) 31
oncology (28) 28
middle aged (25) 25
aged (21) 21
cancer (20) 20
adult (17) 17
ovarian cancer (17) 17
clinical trials (16) 16
chemotherapy (13) 13
ovarian neoplasms - drug therapy (13) 13
treatment outcome (13) 13
analysis (12) 12
hematology, oncology and palliative medicine (11) 11
ovarian neoplasms - pathology (11) 11
aged, 80 and over (10) 10
care and treatment (10) 10
disease-free survival (10) 10
mutation (10) 10
patients (10) 10
tumors (10) 10
research (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
bevacizumab (8) 8
cancer therapies (8) 8
male (8) 8
ovarian neoplasms - genetics (8) 8
quality of life (8) 8
solid tumors (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
neoplasm staging (7) 7
antineoplastic agents - administration & dosage (6) 6
antineoplastic agents - adverse effects (6) 6
breast cancer (6) 6
carcinoma (6) 6
homologous recombination (6) 6
ovarian neoplasms - mortality (6) 6
time factors (6) 6
abridged index medicus (5) 5
administration, oral (5) 5
antineoplastic agents (5) 5
antineoplastic agents - therapeutic use (5) 5
article (5) 5
brca1 protein - genetics (5) 5
brca2 protein - genetics (5) 5
breast-cancer (5) 5
drug administration schedule (5) 5
drug therapy (5) 5
follow-up studies (5) 5
medicine & public health (5) 5
neoplasm recurrence, local - drug therapy (5) 5
open-label (5) 5
poly polymerase (5) 5
surgery (5) 5
therapy (5) 5
angiogenesis (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
biomarkers (4) 4
canada (4) 4
deoxyribonucleic acid--dna (4) 4
disease progression (4) 4
diseases (4) 4
double-blind method (4) 4
health aspects (4) 4
medical prognosis (4) 4
medicine (4) 4
medicine, general & internal (4) 4
multicenter (4) 4
neoplasm grading (4) 4
neoplasms - drug therapy (4) 4
paclitaxel - administration & dosage (4) 4
platinum (4) 4
prognosis (4) 4
radiotherapy (4) 4
studies (4) 4
trial (4) 4
young adult (4) 4
abdomen (3) 3
adjuvant treatment (3) 3
antimitotic agents (3) 3
brca1 (3) 3
carboplatin - administration & dosage (3) 3
carcinoma, ovarian epithelial (3) 3
combination (3) 3
dosage and administration (3) 3
dose-response relationship, drug (3) 3
drug resistance, neoplasm (3) 3
epithelial ovarian (3) 3
fallopian tube neoplasms - drug therapy (3) 3
genetics (3) 3
guidelines (3) 3
heterozygosity (3) 3
infusions, intravenous (3) 3
inhibitor drugs (3) 3
neoplasm recurrence, local (3) 3
neoplasms (3) 3
neoplasms - pathology (3) 3
neoplasms, glandular and epithelial - drug therapy (3) 3
niacinamide - analogs & derivatives (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 799 - 808
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2016, Volume 96, Issue 5, pp. 994 - 1002
Purpose Locoregional recurrence is common after surgery for gastric cancer. Adjuvant therapy improves outcomes but with toxicity. This phase 1/2 study... 
Radiology | Hematology, Oncology and Palliative Medicine | SURGERY | GASTROESOPHAGEAL CANCER | METAANALYSIS | LYMPHADENECTOMY | ONCOLOGY | ADENOCARCINOMA | CHEMORADIATION | CHEMORADIOTHERAPY | QUALITY-OF-LIFE | RADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | III TRIAL | Medication Adherence - statistics & numerical data | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Antineoplastic Agents - administration & dosage | Radiotherapy, Image-Guided | Neoplasm Recurrence, Local - mortality | Cisplatin - administration & dosage | Fluorouracil - administration & dosage | Radiation-Sensitizing Agents - administration & dosage | Antineoplastic Agents - adverse effects | Adult | Female | Drug Administration Schedule | Stomach Neoplasms - therapy | Radiation-Sensitizing Agents - adverse effects | Chemoradiotherapy, Adjuvant - methods | Maximum Tolerated Dose | Cisplatin - adverse effects | Quality of Life | Aged | Stomach Neoplasms - surgery | Stomach Neoplasms - mortality | Care and treatment | Radiation | Adjuvant treatment | Radiotherapy | Health aspects | Stomach cancer | Cisplatin | Cancer | Fluorouracil | Index Medicus | PATIENTS | NEOPLASMS | IMAGES | MAGNESIUM 40 | RADIOLOGY AND NUCLEAR MEDICINE | RADIATION DOSES | TOXICITY | FLUORINE COMPOUNDS | GY RANGE 10-100 | CHEMOTHERAPY
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2016, Volume 94, Issue 1, pp. 111 - 117
Purpose Preclinical studies have shown that angiogenesis inhibition can improve response to radiation therapy (RT). The purpose of this phase 1 study was to... 
Radiology | Hematology, Oncology and Palliative Medicine | UTERINE CERVIX | TRIALS | LATE TOXICITY | ONCOLOGY | BEVACIZUMAB | CISPLATIN CHEMOTHERAPY | FLUID PRESSURE | RADIOTHERAPY | RTOG 0417 | CARCINOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | UNTREATED PATIENTS | Niacinamide - analogs & derivatives | Uterine Cervical Neoplasms - blood supply | Follow-Up Studies | Carcinoma, Squamous Cell - pathology | Humans | Uterine Cervical Neoplasms - pathology | Antineoplastic Agents - administration & dosage | Oxygen - metabolism | Cisplatin - administration & dosage | Cell Hypoxia | Early Termination of Clinical Trials | Angiogenesis Inhibitors - administration & dosage | Time Factors | Phenylurea Compounds - adverse effects | Female | Angiogenesis Inhibitors - adverse effects | Uterine Cervical Neoplasms - therapy | Chemoradiotherapy - methods | Drug Administration Schedule | Brachytherapy - methods | Niacinamide - adverse effects | Carcinoma, Squamous Cell - therapy | Tumor Burden | Niacinamide - administration & dosage | Radiation Tolerance - drug effects | Phenylurea Compounds - administration & dosage | Partial Pressure | Biomarkers | Carcinoma, Squamous Cell - blood supply | Sects | Care and treatment | Oncology, Experimental | Radiation | Clinical trials | Product development | Research | Radiotherapy | Cervical cancer | Medical imaging equipment | Cancer | Index Medicus | PATIENTS | NEOPLASMS | ANOXIA | RADIATION HAZARDS | BIOLOGICAL MARKERS | RADIOLOGY AND NUCLEAR MEDICINE
Journal Article
by Coleman, Robert L and Coleman, R L and Oza, Amit M and Oza, A M and Lorusso, D and Lorusso, Domenica and Aghajanian, C and Aghajanian, Carol and Oaknin, A and Oaknin, Ana and Dean, A and Dean, Andrew and Colombo, N and Colombo, Nicoletta and Weberpals, Johanne I and Weberpals, J I and Clamp, Andrew and Clamp, A and Scambia, Giovanni and Scambia, G and Leary, A and Leary, Alexandra and Holloway, Robert W and Holloway, R W and Gancedo, M Amenedo and Gancedo, Margarita Amenedo and Fong, Peter C and Fong, P C and Goh, Jeffrey C and Goh, J C and O'Malley, David M and O'Malley, D M and Armstrong, Deborah K and Armstrong, D K and Garcia-Donas, Jesus and Garcia-Donas, J and Swisher, E M and Swisher, Elizabeth M and Floquet, A and Floquet, Anne and Konecny, Gottfried E and Konecny, G E and McNeish, I A and McNeish, Iain A and Scott, C L and Scott, Clare L and Cameron, Terri and Maloney, Lara and Isaacson, Jeff and Goble, Sandra and Grace, Caroline and Harding, Thomas C and Raponi, Mitch and Sun, James and Lin, Kevin K and Giordano, Heidi and Ledermann, J A and Ledermann, Jonathan A and Buck, M and Friedlander, M L and Harnett, P and Kichenadasse, G and Denys, H and Dirix, L and Vergote, I and Elit, L and Ghatage, P and Plante, M and Provencher, D and Welch, S and Gladieff, L and Joly, F and Lortholary, A and Lotz, J and Medioni, J and Tredan, O and You, B and El-Balat, A and Hänle, C and Krabisch, P and Neunhöffer, T and Pölcher, M and Wimberger, P and Amit, A and Kovel, S and Leviov, M and Safra, T and Shapira-Frommer, R and Stemmer, S and Bologna, A and Pignata, S and Sabbatini, R F and Tamberi, S and Zamagni, C and O'Donnell, A and Herraez, A Casado and Guerra, E M and Palacio, I and Romero, I and Sanchez, A and ... and ARIEL3 Investigators and ARIEL3 investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10106, pp. 1949 - 1961
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a mutation or high percentage of... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | SOLID TUMORS | BEVACIZUMAB | OPEN-LABEL | CANCER | HETEROZYGOSITY | EPITHELIAL OVARIAN | CHEMOTHERAPY | Double-Blind Method | Follow-Up Studies | Risk Assessment | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Survival Rate | Treatment Outcome | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Indoles - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Maintenance Chemotherapy - methods | Internationality | Ovarian Neoplasms - therapy | Female | Aged | Molecular Targeted Therapy - methods | Clinical trials | Care and treatment | Carcinoma | Drug therapy | Ovarian cancer | Cancer | Analysis | Chemotherapy | Ovarian carcinoma | Platinum | Biomarkers | Mutation | Cancer therapies | Tumors | Homologous recombination | Central nervous system | Poly(ADP-ribose) | Homology | Genomes | Fallopian tube | ADP | Anticancer properties | Metastases | Homologous recombination repair | Randomization | Pain | Motivation | Ribose | Hemoglobin | Alanine | Anemia | Poly(ADP-ribose) polymerase | Breast cancer | Patients | Survival | Heterozygosity | Abdomen | Polymerase | Inhibitors | Point mutation | Loss of heterozygosity | Antitumor activity | Aspartate aminotransferase | Peritoneum
Journal Article
The Lancet, ISSN 0140-6736, 03/2019, Volume 393, Issue 10177, pp. 1240 - 1253
Epithelial ovarian cancer generally presents at an advanced stage and is the most common cause of gynaecological cancer death. Treatment requires expert... 
PHASE-III TRIAL | ADJUVANT CHEMOTHERAPY | GYNECOLOGIC-ONCOLOGY | MEDICINE, GENERAL & INTERNAL | INTRAPERITONEAL CHEMOTHERAPY | CYTOREDUCTIVE SURGERY | NEOADJUVANT CHEMOTHERAPY | PARP INHIBITOR RUCAPARIB | DOUBLE-BLIND | OPEN-LABEL | OLAPARIB MAINTENANCE THERAPY | Carcinoma, Ovarian Epithelial - genetics | CA-125 Antigen - blood | Humans | Risk Factors | Ovarian Neoplasms - pathology | Carcinoma, Ovarian Epithelial - epidemiology | Molecular Biology - methods | Ovarian Neoplasms - epidemiology | Randomized Controlled Trials as Topic | Ovarian Neoplasms - genetics | BRCA1 Protein - genetics | Carcinoma, Ovarian Epithelial - pathology | Aftercare | Ovarian Neoplasms - therapy | Quality of Life | Adult | Female | Neoplasm Recurrence, Local - epidemiology | Mutation | Carcinoma, Ovarian Epithelial - therapy | Hyperthermia, Induced - methods | Membrane Proteins - blood | BRCA2 Protein - genetics | Medical research | International cooperation | Analysis | Genomics | Adjuvant treatment | Medicine, Experimental | Disease susceptibility | Health aspects | Ovarian cancer | Cancer | Therapy | Ovarian carcinoma | Biological evolution | DNA damage | Homologous recombination | Medical services | Clinical trials | Homology | Subgroups | Surgery | Deoxyribonucleic acid--DNA | BRCA2 protein | Sensitivity analysis | BRCA1 protein | Breast cancer | Disease control | Patients | Abdomen | Quality of life | Womens health | Health risk assessment | Tumors
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer
Journal Article
by Sieh, Weiva, PhD and Köbel, Martin, Dr and Longacre, Teri A, Prof and Bowtell, David D, Prof and deFazio, Anna, PhD and Goodman, Marc T, PhD and Høgdall, Estrid, PhD and Deen, Suha, Prof and Wentzensen, Nicolas, MD and Moysich, Kirsten B, Prof and Brenton, James D, MD and Clarke, Blaise A, MD and Menon, Usha, Prof and Gilks, C Blake, Prof and Kim, Andre, MPH and Madore, Jason, MS and Fereday, Sian, BSc and George, Joshy, MEng and Galletta, Laura, BSc and Lurie, Galina, MD and Wilkens, Lynne R, DrPH and Carney, Michael E, MD and Thompson, Pamela J, MPH and Matsuno, Rayna K, PhD and Kjær, Susanne Krüger, Prof and Jensen, Allan, PhD and Høgdall, Claus, Prof and Kalli, Kimberly R, PhD and Fridley, Brooke L, PhD and Keeney, Gary L, MD and Vierkant, Robert A, MS and Cunningham, Julie M, PhD and Brinton, Louise A, PhD and Yang, Hannah P, PhD and Sherman, Mark E, MD and García-Closas, Montserrat, Prof and Lissowska, Jolanta, PhD and Odunsi, Kunle, Prof and Morrison, Carl, MD and Lele, Shashikant, Prof and Bshara, Wiam, MD and Sucheston, Lara, PhD and Jimenez-Linan, Mercedes, MD and Driver, Kristy, BSc and Alsop, Jennifer, BA and Mack, Marie and McGuire, Valerie, PhD and Rothstein, Joseph H, MS and Rosen, Barry P, Prof and Bernardini, Marcus Q, MD and Mackay, Helen, MD and Oza, Amit, Prof and Wozniak, Eva L, BSc and Benjamin, Elizabeth, MD and Gentry-Maharaj, Aleksandra, PhD and Gayther, Simon A, Prof and Tinker, Anna V, MD and Prentice, Leah M, PhD and Chow, Christine, BMLSc and Anglesio, Michael S, PhD and Johnatty, Sharon E, PhD and Chenevix-Trench, Georgia, Prof and Whittemore, Alice S, Prof and Pharoah, Paul DP, Prof and Goode, Ellen L, PhD and Huntsman, David G, Prof and Ramus, Susan J, PhD
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 9, pp. 853 - 862
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 9, pp. 852 - 861
Summary Background Olaparib (AZD2281) is a small-molecule, potent oral poly(ADP-ribose) polymerase (PARP) inhibitor. We aimed to assess the safety and... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | BRCA2 MUTATIONS | LIPOSOMAL DOXORUBICIN | RIBOSE POLYMERASE INHIBITORS | SOLID TUMORS | ONCOLOGY | GENETICS | GUIDELINES | SENSITIVITY | RESISTANCE | PARP INHIBITOR | Humans | Middle Aged | Ovarian Neoplasms - pathology | Carcinoma - mortality | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Time Factors | Aged, 80 and over | Cell Differentiation | Carcinoma - drug therapy | Enzyme Inhibitors - adverse effects | Phthalazines - administration & dosage | Administration, Oral | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Enzyme Inhibitors - therapeutic use | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | Canada | Breast Neoplasms - genetics | Carcinoma - genetics | Mutation | Receptor, ErbB-2 - analysis | Piperazines - administration & dosage | Receptors, Estrogen - analysis | Ovarian Neoplasms - mortality | Breast Neoplasms - enzymology | Antineoplastic Agents - adverse effects | Carcinoma - enzymology | Adult | Female | Ovarian Neoplasms - drug therapy | Carcinoma - secondary | Biomarkers, Tumor - analysis | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Treatment Outcome | BRCA1 Protein - genetics | Disease-Free Survival | Phthalazines - therapeutic use | Poly(ADP-ribose) Polymerases - metabolism | Breast Neoplasms - pathology | Breast Neoplasms - mortality | Aged | BRCA2 Protein - genetics | Phthalazines - adverse effects | Care and treatment | Relapse | Gene mutations | Oncology, Experimental | Breast cancer | Research | Cancer | Diseases | Index Medicus
Journal Article